Dose intensities were significantly lower in the recurrent groups ( gemcitabine : recurrent group 83.5 % vs unresectable group 96.8 % ; P < 0.01 , S-1 : Recurrent group 75.9 % vs unresectable group 91.8 % ; P < 0.01 ) .